In The News,
Dr. Kolodziej spoke out about the dangers of reopening national coverage determinations at the Florida Society of Clinical Oncology annual meeting
[el-text]
Written by Samantha DiGrande
***excerpt***
“The decision to reopen an NCD is not one that is taken lightly. Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, spoke out from the crowd during the panel. CMS may consider reopening the Foundation Medicine NCD to address the application of the NCD to solid tumors, hereditary cancers, and the appropriate clinical decision to test more than once, among other issues.”
***end excerpt***
***
[/el-text]